Please login to the form below
morphosys
This page shows the latest morphosys news and features for those working in and with pharma, biotech and healthcare.
Incyte signs lymphoma deal worth up to $1.1bn with MorphoSys
Under the terms of the deal, Incyte is paying MorphoSys $750m upfront, as well as making an equity investment worth $150m in the company. ... MorphoSys is also eligible to receive milestone payments worth up to $1.1bn, in addition to any royalties from
Latest news
-
J&J’s new Darzalex formulation OK’d for use in Europe
More competition could also come from MorphoSys and Takeda, which both have anti-CD38 drugs in late-stage studies for myeloma.
-
MorphoSys drops Novartis-partnered drug in eczema after phase 2 miss
Therapy candidate was licensed in a $1bn-plus deal last year. Germany’s MorphoSys has abandoned an atopic dermatitis drug licensed by Novartis in a $1bn-plus deal last year after ... The decision to drop MOR106, a selective IL-17c inhibitor
-
FDA verdict on Sanofi’s Darzalex rival is due in April 2020
Additional competition is however looming from MorphoSys and Takeda, which each have anti-CD38 drugs in pivotal-stage testing for myeloma, while another rival is Bristol-Myers Squibb and AbbVie’s
-
GSK pushes rheumatoid arthritis antibody into phase 3
GSK acquired the rights to otilimab from MorphoSys in a 445m deal agreed in 2013, and the German biotech stands to a receive a 22m milestone payment with the start of
-
MorphoSys eyes 2020 launch for lymphoma CAR-T challenger
New trial data has set up a US filing later this year for MorphoSys’ anti-CD19 antibody tafasitamab (MOR208) – and a possible challenge to Novartis and Gilead’s CAR-T therapies. ... The L-MIND data raise the likelihood of MorphoSys attracting a
More from news
Approximately 5 fully matching, plus 17 partially matching documents found.
Latest Intelligence
-
European biotech: a new generation of leaders emerges
Morphosys. One of Europe’s star performers over the last two to three years has been Germany’s Morphosys. ... Unlike many other European biotechs, Morphosys isn’t seeking a marketing partner for the launch of its lead product, and aims to go it
-
Deal Watch November 2016
acquisition - company. 125+. MorphoSys/ Leo Pharma. discovery and development of mAbs for skin diseases.
-
Pharma deals in March 2015
In the same area is Morphosys which has been less fortunate this month because of the termination of its $818m agreement with Celgene to develop a Mab for treatment of multiple ... myeloma. Morphosys' share price fell by over 20%. This is an
-
Deal Watch table for August 2014
187. Emergent BioSolutions/ Morphosys. Licence, joint development &commercialisation. MOR209/ES414, anti-PSMA/anti-CD3 bi-specific antibody targeting prostate cancer (preclinical).
-
Pharma deals during August 2014
These include the usual sprinkling of small molecule (Millennium/ Infinity, Hanmi/ Luye, Ziopharm/ Solasia) and antibody (Emergent/ Morphosys) approaches but also more alternative approaches as exemplified by the Gamida/ Novartis agreement.
More from intelligence
Approximately 0 fully matching, plus 9 partially matching documents found.
Latest appointments
-
Pharma industry appointments
Lemus was also chief executive officer of Sigma Tau Pharmaceuticals and chief financial officer and executive vice president of MorphoSys, where he took the company public in 1999.
-
Robert Freisen joins Ablynx
He has previously held roles for ProQR Therapeutics, Janssen BioTherapeutics, and MorphoSys.
-
Dave Lemus joins Proteros as an executive board member
He has also held roles with MorphoSys and Hoffman La Roche.
-
MorphoSys appoints Dr Markus Enzelberger as CSO
He succeeds Dr Marlies Sproll who resigns. German biotech MorphoSys has appointed Dr Markus Enzelberger as its new chief scientific officer following his predecessor, Dr Marlies Sproll’s resignation. ... Dr Gerald Moller, supervisory board chairman,
-
MC Services welcomes Dr Claudia Gutjahr-Loeser to its management team
She joins the PR firm from MorphoSys, where she was senior VP. ... She joins the Duesseldorf, Germany-based firm from MorphoSys, where she headed the corporate communications and investor relations department as senior vice president; a role that saw her
More from appointments
Approximately 3 fully matching, plus 6 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- AZ strengthens Daiichi Sankyo partnership with new ADC deal
- Novavax reports promising phase 1 results for coronavirus vaccine
- China’s CanSino Biologics reveals phase 2 coronavirus vaccine results
- AbbVie exits Voyager alliance for Alzheimer’s/Parkinson’s gene therapies
- How will the events and exhibitions industry change post-Coronavirus?
- Novartis builds its case for novel MS treatment ofatumumab
- Novavax plans to meet US COVID-19 vaccine demand in 2021
- Sinovac begins late-stage COVID-19 vaccine trial
- Seres’ microbiome-based therapy hits the mark in phase 3
- Planning your clinical trial? Why you need to engage patients sooner
- Live Webinar: Re imagining Healthcare through Integrated Digital Health Empowerment
- Combating Coronavirus Through Reversing Diabetes
PMHub
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...
Latest intelligence
- Planning your clinical trial? Why you need to engage patients sooner
- It’s highly likely that clinical studies are deterring patients based on decisions made in the early stages, such as during planning and design....
- Patient-centricity in improving patient recruitment advertising
- This blog looks into the importance of concepts and patient centricity in patient recruitment....
- AI: the smart money is on the smart thinking
- Looking at the three key areas where AI is being applied: drug discovery, clinical decision-making and clinical trials...
Quick links
Infographics
